Although upper gastrointestinal (GI) bleeding from stress-related mucosal disease (SRMD) in critically ill patients is common, significant bleeding with hemodynamic instability is not. Risk factor assessment can assist in identifying patients with a greater likelihood of developing significant SRMD. Prophylaxis against stress ulcer bleeding with luminal agents (eg, antacids and sucralfate) or drugs that inhibit acid secretion (eg, histamine 2-receptor antagonists [H2RAs] and proton-pump inhibitors [PPIs]) can reduce major bleeding but has little or no effect on mortality. Currently, the mainstays of prophylactic therapy for SRMD are intravenously administered H2RAs and PPIs. Wider usage of PPIs reflects their enhanced efficacy in suppressing acid secretion as well as lack of tolerance for H2RAs. Guidelines for the prophylactic use of H2RAs or PPIs in treatment of SRMD will require large, randomized studies that also examine cost effectiveness of individual strategies.
KeywordsOmeprazole Intensive Care Unit Patient Lansoprazole Misoprostol Esomeprazole
Unable to display preview. Download preview PDF.
References and Recommended Reading
- 1.Spechler SJ: Peptic ulcer disease and its complications. In Gastrointestinal and Liver Disease, edn 7. Edited by Feldman M, Friedman LS, Sleisenger MH. Philadelphia: Saunders; 2002:747–781.Google Scholar
- 2.Haglund U: Stress ulcers. Scand J Gastroenterol 1990, 25(Suppl 175):27–33.Google Scholar
- 6.Cook DJ, Fuller HD, Guyatt GH, et al.: Risk factors for gastrointestinal bleeding in critically ill patients. Canadian Critical Care Trials Group. N Engl J Med 1994, 330:377–381. A large, prospective, randomized, multicenter study linking coagulopathy and respiratory failure in the causation of clinically significant upper GI bleeding in critically ill patients.PubMedCrossRefGoogle Scholar
- 13.Chung LY, Ashley SW: Gastric blood flow and mucosal defense mechanisms. Clin Invest Med 1987, 10:201–208.Google Scholar
- 17.Hoogerwerf WA, Pasricha PJ: Pharmacotherapy of gastric acidity, peptic ulcers and gastroesophageal reflux disease. In Goodman & Gilman’s The Pharmacological Basis of Therapeutics, edn 11. Edited by Brunton LL, Lazo JS, Parker KL, et al. Columbus, OH: McGraw-Hill; 2006:1005–1020.Google Scholar
- 20.Phillips JO, Metzler MH, Huckfeldt RE, et al.: A multicenter, prospective, randomized clinical trial of continuous infusion I.V. ranitidine vs omeprazole suspension in the prophylaxis of stress ulcers. Crit Care Med 1998, 26:A101.Google Scholar
- 21.Azevedo JR, Soares MG, Silva G, Palacio G: Prevention of stress ulcer bleeding in high risk patients: comparison of three drugs [abstract]. Crit Care Med 1992, 27:A41.Google Scholar